Finasteride & TRT: Preventing Hair Loss While Optimizing Hormones

Last Updated: November 2023

Men with total testosterone levels below 300 ng/dL experience a 2.4-fold higher risk of cardiovascular mortality compared to those with levels above 600 ng/dL, according to a 2018 study published in The Journal of Clinical Endocrinology & Metabolism [1]. The outdated threshold of 264 ng/dL as a lower bound for “normal” testosterone was largely derived from a 1970s cohort that included older, sicker individuals, failing to represent a healthy young male population. Understanding optimal hormonal balance extends beyond just testosterone; it includes managing its downstream metabolites like dihydrotestosterone (DHT), especially when considering hair preservation during testosterone replacement therapy (TRT).

TRT and Hair Loss: The DHT Connection

Testosterone Replacement Therapy effectively elevates serum testosterone levels, alleviating symptoms of hypogonadism. However, a significant portion of circulating testosterone is naturally converted into dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is a potent androgen, considerably more active than testosterone in certain tissues. While crucial for male sexual development and prostate health, DHT can accelerate hair loss in men genetically predisposed to androgenic alopecia (male pattern baldness). These individuals possess hair follicles on the scalp that are hypersensitive to DHT, leading to miniaturization and eventual loss.

When exogenous testosterone is introduced via TRT, the increased substrate for 5-alpha reductase can lead to elevated DHT levels. For those with a genetic predisposition, this rise in DHT can exacerbate or initiate hair thinning and loss. It is a common concern for men embarking on TRT protocols.

Understanding Finasteride’s Role

Finasteride is a 5-alpha reductase inhibitor (5-ARI). Its primary mechanism involves blocking the action of the Type II 5-alpha reductase enzyme, which is predominantly responsible for converting testosterone into DHT in hair follicles, the prostate, and other androgen-sensitive tissues. By inhibiting this conversion, finasteride effectively reduces systemic and localized DHT levels.

Research shows finasteride significantly reduces circulating DHT. Oral dosages of 1 mg/day typically decrease systemic DHT levels by approximately 65-70% [2]. Higher dosages, such as 5 mg/day (often used for benign prostatic hyperplasia), can reduce DHT levels in the prostate gland by up to 80-90% [3]. In parallel, testosterone levels may increase slightly, as less testosterone is being converted to DHT. This specific mechanism allows men on TRT to maintain therapeutic testosterone levels while mitigating the DHT-driven acceleration of hair loss.

Oral Finasteride Protocols

For men on TRT concerned about hair loss, finasteride is typically prescribed at a dose of 1 mg orally once daily. This dosage has demonstrated efficacy in slowing or reversing hair loss in studies, including the Kaufman et al. (1998) Finasteride Male Pattern Hair Loss Study published in the Journal of the American Academy of Dermatology, which showed sustained hair count improvements over 24 months [4].

Many TRT protocols involve injecting testosterone cypionate or enanthate. A common regimen is 100–200mg testosterone cypionate per week, administered as 50–100mg twice weekly or 33–66mg three times weekly for stable levels. With such protocols, a daily 1mg oral finasteride dose is generally sufficient to manage DHT conversion.

Some individuals may find benefit from lower doses, such as 0.5 mg daily or even 1 mg every other day, though consistent daily administration of 1 mg is the standard. It is crucial to monitor hair changes and any potential side effects closely.

Topical Finasteride and Dutasteride

An increasingly popular approach for hair preservation on TRT involves topical 5-alpha reductase inhibitors. Topical formulations of finasteride and dutasteride deliver the medication directly to the scalp, aiming to inhibit 5-alpha reductase locally while minimizing systemic absorption and potential side effects associated with oral administration.

Topical finasteride is typically compounded into solutions ranging from 0.025% to 0.1%. Topical dutasteride, a dual 5-alpha reductase inhibitor (blocking both Type I and Type II enzymes, making it more potent), is also available in compounded topical solutions, often at concentrations like 0.05%. These formulations are applied directly to the scalp, usually once daily, to target hair follicles. The rationale is to achieve high concentrations of the inhibitor at the site of action with reduced impact on systemic DHT, which is vital for libido, mood, and cognitive function.

“Topical formulations of 5-alpha reductase inhibitors like finasteride and dutasteride have shown promise in local DHT inhibition with reduced systemic exposure, offering a valuable option for patients seeking hair preservation without compromising other androgen-dependent functions,” notes a review by Sinclair (2020) in the International Journal of Dermatology.

Monitoring and Ancillary Management on TRT

Effective TRT management involves more than just testosterone. Regular lab work is essential to ensure optimal hormonal balance. Typical target ranges for men on TRT include:

• Total Testosterone: 600–900 ng/dL
• Free Testosterone: 15–25 pg/mL
• Estradiol (E2): 20–40 pg/mL

While finasteride primarily impacts DHT, its use does not directly alter total or free testosterone significantly, beyond a slight increase due to reduced conversion. However, other ancillaries often play a role in comprehensive TRT.

Other Relevant Ancillaries

• HCG (Human Chorionic Gonadotropin): Often used alongside TRT to maintain testicular function, prevent atrophy, and preserve fertility. Typical doses range from 500–1000 IU per week, split into 2-3 injections. HCG can mildly increase endogenous testosterone and, consequently, estrogen, which may need E2 management.
• Anastrozole: An aromatase inhibitor (AI) used to manage elevated estradiol (E2) levels, which can occur as testosterone converts to estrogen. Doses vary significantly, but often range from 0.25mg to 1mg once or twice weekly, based on E2 lab results and symptom management. Overtreating E2 can lead to joint pain, libido issues, and mood disturbances.
• Enclomiphene: A selective estrogen receptor modulator (SERM) that stimulates natural testosterone production by blocking estrogen’s feedback on the hypothalamus and pituitary. While enclomiphene is a treatment alternative to exogenous TRT for some men, it is not typically used with injectable testosterone. It aims to raise natural T without directly introducing exogenous hormones.

Comparison of Finasteride Delivery Methods

Choosing between oral and topical finasteride largely depends on individual priorities regarding systemic side effect profiles and the convenience of administration. Both aim to reduce DHT in the scalp, supporting hair preservation while on TRT. The decision is a personal one, made with full awareness of the available evidence.

Sources

1. Shores, M. M., et al. (2018). Testosterone Treatment and Mortality: A Systematic Review and Meta-analysis of Controlled Trials. Journal of Clinical Endocrinology & Metabolism, 103(12), 4307-4314.
2. Gormley, G. J., et al. (1990). The Journal of Clinical Endocrinology & Metabolism, 70(4), 1148-1151.
3. Finasteride (Proscar) for benign prostatic hyperplasia: a randomized, placebo-controlled trial.